Additional agents are under investigation for treatment of CAR related toxicities including Siltuximab, a direct IL-6-targeting antibody, and Anakinra, an anti-IL-1 receptor antagonist that has been shown to have efficacy in CAR-mediated Hemophagocytic Lymphohistiocytosis (HLH), a post-CAR toxicity on the spectrum of severe CRS seen following CD19-CAR T cell therapy (35) and recently reported to have greater frequency following CD22-CAR T cell therapy (36). Here, IL6 is linked to hemophagocytic syndrome.